Editas Medicine Inc (NASDAQ: EDIT) on Friday, plunged -2.13% from the previous trading day, before settling in for the closing price of $1.41. Within the past 52 weeks, EDIT’s price has moved between $1.12 and $11.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 135.89% over the past five years. The company achieved an average annual earnings per share of -33.69%. With a float of $81.78 million, this company’s outstanding shares have now reached $82.54 million.
Let’s look at the performance matrix of the company that is accounted for 265 employees. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 67.71%. The most recent insider transaction that took place on Dec 03 ’24, was worth 3,361. In this transaction CEO of this company sold 1,618 shares at a rate of $2.08, taking the stock ownership to the 312,106 shares. Before that another transaction happened on Dec 03 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for $2.08, making the entire transaction worth $1,124. This insider now owns 133,354 shares in total.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -33.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.23% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Editas Medicine Inc (EDIT) is currently performing well based on its current performance indicators. A quick ratio of 3.75 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.39 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Editas Medicine Inc (NASDAQ: EDIT) saw its 5-day average volume 2.76 million, a positive change from its year-to-date volume of 2.75 million. As of the previous 9 days, the stock’s Stochastic %D was 76.14%. Additionally, its Average True Range was 0.14.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 8.67%, which indicates a significant decrease from 57.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.41% in the past 14 days, which was higher than the 84.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7938, while its 200-day Moving Average is $3.8763. Nevertheless, the first resistance level for the watch stands at $1.4600 in the near term. At $1.5400, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6000. If the price goes on to break the first support level at $1.3200, it is likely to go to the next support level at $1.2600. Assuming the price breaks the second support level, the third support level stands at $1.1800.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
Market capitalization of the company is 113.92 million based on 82,548K outstanding shares. Right now, sales total 78,120 K and income totals -153,220 K. The company made 60 K in profit during its latest quarter, and -62,140 K in sales during its previous quarter.
